Rev Esp Quimioter 2017, 30(5): 312-318

Streptococcus agalactiae: prevention and vaccine development

ALBERTO PUERTAS-PRIETO, ANA LARA-OYA, CARMEN LIÉBANA MARTOS, JAVIER RODRÍGUEZ-GRANGER, FERNANDO COBO, ANTONIO SAMPEDRO, ANASTASIA PADILLA, JOSÉ GUTIÉRREZ-FERNÁNDEZ, SEBASTIÁN MANZANARES-GALÁN, MARINA CUETO-LÓPEZ, MANUEL ROSA-FRAILE, JOSÉ MARÍA NAVARRO-MARI

Streptococcus agalactiae, group B Streptococcus (SGB), is the most important cause of morbi-mortality among newborn population, and an important pathogen among immunossupressed adult patients. Despite the advances in the treatment and prevention of neonatal infections as a consequence of implementation of national and international recommendations for prevention of infection, there are still some improvements for the final control of the disease. In this sense, the vaccination against SGB could be an effective measure for the prevention of disease in those cases where intrapartum prophylaxis is not useful and in adult patients with risk factors for invasive infection due to SGB. This review summarizes the efforts made until now in order to establish the control of the infection, and brings some information on the current state-of-the art of vaccines against SGB, in which different strategies in their design have been used.

Rev Esp Quimioter 2017; 30(5): 312-318 [Texto completo – PDF]